Context Therapeutics (CNTX), a biopharmaceutical company, on Wednesday, announced the dosing of the first patient in its Phase 1 clinical trial of CTIM-76 in CLDN6-positive gynecologic and testicular cancers.
The trial will enroll up to 70 patients, and initial data is expected to be shared in the first half of 2026.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com